Check-Cap Ltd. (CHEK): Price and Financial Metrics
CHEK Price/Volume Stats
Current price | $3.11 | 52-week high | $4.63 |
Prev. close | $2.75 | 52-week low | $1.25 |
Day low | $2.51 | Volume | 439,300 |
Day high | $3.45 | Avg. volume | 259,495 |
50-day MA | $2.14 | Dividend yield | N/A |
200-day MA | $2.83 | Market Cap | 18.19M |
CHEK Stock Price Chart Interactive Chart >
Check-Cap Ltd. (CHEK) Company Bio
Check-Cap Ltd. is a clinical stage medical diagnostics company engaging in the development of ingestible imaging capsule system for colorectal cancer screening. The company was founded by Yoav Kimchy in April 2005 and is headquartered in Isfiya, Israel.
Latest CHEK News From Around the Web
Below are the latest news stories about CHECK-CAP LTD that investors may wish to consider to help them evaluate CHEK as an investment opportunity.
SYMETRYX COMMENTS ON SUCCESSFUL CAMPAIGN AT CHECK-CAP LTDSymetryx Corporation ("Symetryx"), a Canadian venture company, is pleased to announce that the shareholders of Check-Cap Ltd. (NASDAQ: CHEK) voted overwhelmingly to elect all the director nominees proposed by Symetryx at the Annual General Meeting held on December 18th 2023. The CHEK shareholders, amongst other matters, voted overwhelmingly not to approve the proposed merger with Keystone Dental. |
Check-Cap Board of Directors Issues Letter to ShareholdersISFIYA, Israel, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Check-Cap, Ltd. (the “Company” or “Check-Cap”) (NASDAQ: CHEK) today issued the following letter from its Board of Directors to its shareholders and to the investment community: Dear Check-Cap Shareholders, The Board of Directors wishes to inform shareholders and the broader investment community that on December 12, 2023, Check-Cap won a motion filed by Symetryx in Israeli court, with the Court rejecting all claims raised by Symetryx, including th |
CHECK- CAP BOARD MEMBER'S STATEMENT ON THE STAND SUGGESTS A POTENTIAL CONFLICT OF INTEREST WITH KEYSTONE DENTALFurther to its news release of November 28, 2023, Symetryx continues to urge its fellow Check-Cap Ltd. ("Check-Cap") (NASDAQ: CHEK) shareholders to VOTE AGAINST the Keystone Dental and FOR the Symetryx slate of highly qualified and independent director nominees. See Symetryx Today Issues Open Letter to Shareholders In Regard to the Upcoming Annual General Meeting (newswire.ca) |
CITING THE MANY FDA ADVERSE EFFECTS TO KEYSTONE DENTAL - CHECK-CAP FOUNDER STRONGLY RECOMMENDS VOTING AGAINST THE KEYSTONE DENTAL MERGER ALSO RECOMMENDS VOTING FOR THE SYMETRYX BOARD NOMINEESFurther to its news release of November 28, 2023, Symetryx continues to urge its fellow Check-Cap Ltd. ("Check-Cap") (NASDAQ: CHEK) shareholders to VOTE AGAINST the Keystone Dental and FOR the Symetryx slate of highly qualified and independent director nominees. See Symetryx Today Issues Open Letter to Shareholders In Regard to the Upcoming Annual General Meeting (newswire.ca) |
CHECK-CAP FOUNDER STRONGLY RECOMMENDS VOTING AGAINST THE KEYSTONE DENTAL MERGER AND FOR THE SYMETRYX BOARD OF DIRECTORS NOMINEESToday, Symetryx Corporation ("Symetryx") once again encourages our fellow shareholders of Check-Cap Ltd. ("Check-Cap") (NASDAQ: CHEK) to review the news release issued by Yoav Kimchy, PhD, the Founder and former Chief Technology Officer, and shareholder, of Check-Cap, who has stated in an open letter to his fellow shareholders that the value of the Intellectual Property of Check-Cap was, in essence, disregarded and assigned no monetary value when valuing the Keystone Dental transaction. See Chec |
CHEK Price Returns
1-mo | 38.84% |
3-mo | 49.52% |
6-mo | -27.00% |
1-year | 117.48% |
3-year | -90.96% |
5-year | -94.24% |
YTD | 49.52% |
2023 | -5.45% |
2022 | -83.70% |
2021 | 46.67% |
2020 | -73.26% |
2019 | -20.00% |
Loading social stream, please wait...